RE:RE:RE:RE:RE:RE:Spectral on Linkedin Today Much higher, but only if you believe that standard Biotech revenue and EBITDA multiples come into play when trying to put a fair valuation on Spectral
Here's a relevant site :
https://finerva.com/report/biotech-genomics-2024-valuation-multiples/
"BioTech companies are regularly acquired at multi-billion valuations even before they make their first revenues."
They say 5.7X as a revenue multiple is the 2022 going rate - down from 10X in 2020 and 2021
What does Spectral say is the market potential ( for the USA only)? More than $2B ! Using the paltry 5.7X multiple it implies a gross valuation ( full USA only penetration ) of a mere $11.4B USD
Doing the math, you'll need to take into account a discount to account for a period of time for medical uptake, time value of money and of course, about 400 million shares o/s
Lets assume only 10% of the potential is achieved = $1.14B
Divided by 400m shares
= $2.85 USD
or about $4 CAD
10% seems low to me - for a new SoC , that excludes Canadian revenues and of course,worldwide sales of EAA
So ya, your $5 calc seems fair ( conservative....but fair)
Gets even better if you use common EBITDA multiples.
MM